[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545697":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":51,"centralContacts":56,"locations":62,"responsibleParty":80,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":60,"eligibilityCriteria":91,"healthyVolunteers":88,"sex":92,"minAge":93,"maxAge":60,"enrollmentInfo":94,"targetDuration":60,"studyType":97,"phases":98,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":65,"whyStopped":60,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Boston University","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin K1 500 µg","EXPERIMENTAL","Participants randomized to this arm will take one Vitamin K1 500 µg pill daily for 4 weeks.",[13],"Drug: Vitamin K1 500 µg",{"label":15,"type":10,"description":16,"interventionNames":17},"Vitamin K1 1000 µg","Participants randomized to this arm will take one Vitamin K1 1000 µg pill daily for 4 weeks.",[18],"Drug: K1 1000 µg",{"label":20,"type":10,"description":21,"interventionNames":22},"Vitamin K2 (MK-7) 300 µg","Participants randomized to this arm will take one Vitamin K2 (MK-7) 300 µg pill daily for 4 weeks.",[23],"Drug: Vitamin K2 (MK-7) 300 µg",{"label":25,"type":26,"description":27,"interventionNames":28},"Placebo","PLACEBO_COMPARATOR","Participants randomized to this arm will take 1 placebo pill daily for 4 weeks.",[29],"Other: Placebo",[31,37,42,46],{"type":32,"name":9,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","One pill daily for 4 weeks.",[9],[36],"Phylloquinone 500 µg",{"type":32,"name":38,"description":33,"armGroupLabels":39,"otherNames":40},"K1 1000 µg",[15],[41],"Phylloquinone 1000 µg",{"type":32,"name":20,"description":33,"armGroupLabels":43,"otherNames":44},[20],[45],"Menaquinone 300 µg",{"type":6,"name":25,"description":47,"armGroupLabels":48,"otherNames":49},"Placebo pill daily for 4 weeks.",[25],[50],"Sugar pill",[52],{"name":53,"affiliation":54,"role":55},"Jean Liew, MD MS","Boston University Chobanian & Avedisian School of Medicine, Department of Rheumatology","PRINCIPAL_INVESTIGATOR",[57],{"name":53,"role":58,"phone":59,"phoneExt":60,"email":61},"CONTACT","617 358 9655",null,"jwliew@bu.edu",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Boston Medical Center, Rheumatology Clinic","RECRUITING","Boston","Massachusetts","02118","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-71.05977,42.35843,{"lat":75,"lon":74},[78],{"name":53,"role":58,"phone":79,"phoneExt":60,"email":61},"617-358-9655",{"type":81,"investigatorFullName":60,"investigatorTitle":60,"investigatorAffiliation":60,"oldNameTitle":60,"oldOrganization":60},"SPONSOR",[83],{"name":84,"class":85},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH","100545697","phase-1-the-role-of-vitamin-k-on-knee-osteoarthritis-outcomes-100545697",false,"NCT06385275","The Role of Vitamin K on Knee Osteoarthritis Outcomes","Inclusion Criteria:\n\n* ≥60 years old\n* Clinical diagnosis of knee OA by the treating rheumatologist\n* English fluency\n\nExclusion Criteria:\n\n* Anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)","ALL","60 Years",{"count":95,"type":96},55,"ESTIMATED","INTERVENTIONAL",[99,100],"PHASE1","PHASE2","The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known,\n\nThe overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.",[103],"Osteo Arthritis Knee",[105,106,107,108,109],"Vitamin K-1","Vitamin K-2","Menaquinone-7 (MK-7)","Uncarboxylated matrix Gla protein (ucMGP)","Phylloquinone","2026-01-21",{"date":112,"type":113},"2026-01-23","ACTUAL",{"date":115,"type":113},"2025-06-03",{"date":117,"type":96},"2026-12",{"name":5,"class":6},1]